Keytruda wins eighth FDA approval of 2021, moving into adjuvant and pediatric melanoma settings
Keytruda made history seven years ago as the first anti-PD-1 therapy approved in the US, winning an OK in metastatic melanoma. The drug has since …
Sign up to read this article for free.
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.
